Search

Your search keyword '"Lorusso, Domenica"' showing total 28 results

Search Constraints

Start Over You searched for: Author "Lorusso, Domenica" Remove constraint Author: "Lorusso, Domenica" Topic immunotherapy Remove constraint Topic: immunotherapy
28 results on '"Lorusso, Domenica"'

Search Results

1. Immunotherapy in MMR-d/MSI-H recurrent/metastatic endometrial cancer.

2. Best original research presented at the 24 th European Congress on Gynaecological Oncology-Best of ESGO 2023.

3. Emerging role of immune checkpoint inhibitors in the treatment of ovarian cancer.

4. Investigating the role of immunotherapy in advanced/recurrent female genital tract melanoma: a preliminary experience.

6. Endometrial and Cervical Cancers

7. Dostarlimab: From preclinical investigation to drug approval and future directions

8. Lynch Syndrome and Gynecologic Tumors: Incidence, Prophylaxis, and Management of Patients with Cancer.

9. DOMENICA study (GINECO-EN105b/ENGO-Ten13): randomized phase III trial in MMR deficient (MMRd) endometrial cancer (EC) patients comparing chemotherapy (CT) alone versus dostarlimab in first line advanced/metastatic setting (APGOT-EN1).

10. Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon?

11. Beyond Platinum, ICIs in Metastatic Cervical Cancer: A Systematic Review.

12. How Immunotherapy Modified the Therapeutic Scenario of Endometrial Cancer: A Systematic Review.

13. The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy.

14. Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis.

15. Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer --a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34).

16. Investigating the role of immunotherapy in advanced/ recurrent female genital tract melanoma: a preliminary experience.

17. Antitumor activity and safety of the PD-1 inhibitor retifanlimab in patients with recurrent microsatellite instability-high or deficient mismatch repair endometrial cancer: Final safety and efficacy results from cohort H of the POD1UM-101 phase I study.

18. Tisotumab vedotin in recurrent or metastatic cervical cancer.

19. Oncologic Drugs Approval in Europe for Solid Tumors: Overview of the Last 6 Years.

20. Adoptive immunotherapy with cytokine-induced killer cells generated with a new good manufacturing practice-grade protocol.

21. Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives.

22. Role of Immune Checkpoint Inhibitors in Cervical Cancer: From Preclinical to Clinical Data.

23. Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point Inhibitors.

24. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial.

25. The role of immunotherapy in advanced and recurrent MMR deficient and proficient endometrial carcinoma.

26. Clear cell carcinoma of the endometrium.

27. Uterine serous carcinoma.

28. Advanced and recurrent endometrial cancer: State of the art and future perspectives.

Catalog

Books, media, physical & digital resources